| 原发性胆汁性肝硬化的药物治疗进展 |
| |
| 引用本文： | 张华伟,张艳,杨镜,徐凌,卢洁,郭传勇.原发性胆汁性肝硬化的药物治疗进展[J].世界临床药物,2014(4):253-256. |
| |
| 作者姓名： | 张华伟 张艳 杨镜 徐凌 卢洁 郭传勇 |
| |
| 作者单位： | [1]苏州大学附属第一医院消化科,苏州215006 [2]同济大学附属第十人民医院消化科,上海200072 |
| |
| 基金项目： | 国家自然科学基金（编号：81270515）. |
| |
| 摘 要： | 原发性胆汁性肝硬化（PBC）是一种病因未明的慢性进行性胆汁淤积性肝脏疾病。熊去氧胆酸是目前最具循证医学支持的PBC治疗药物，但约40％PBC患者对熊去氧胆酸治疗应答不良。本文综述糖皮质激素、免疫抑制剂、贝特类降脂药、抗逆转录病毒药物以及利妥昔单抗等临床常用药物和某些临床有可能选用的联合治疗方案。
|
| 关 键 词： | 原发性胆汁性肝硬化 药物治疗 熊去氧胆酸 |
Drug therapy of primary biliary cirrhosis |
| |
| ZHANG Hua-wei,ZHANG Yan,YANG Jing,XU Ling,LU Jie,GUO Chuan-yong.Drug therapy of primary biliary cirrhosis[J].WORLD CLINICAL DRUGS,2014(4):253-256. |
| |
| Authors: | ZHANG Hua-wei ZHANG Yan YANG Jing XU Ling LU Jie GUO Chuan-yong |
| |
| Institution: | 1. Department of Gastroenterology, First Affiliated Hospital of Soochow University, Suzhou 215006; 2. Department of Gastroenterology, 10th People＇s Hospital of Tongfi University, Shanghai 200072, China) |
| |
| Abstract: | Primary biliary cirrhosis （PBC） is an unknown etiological chronic progressive cholestatic liver disease. Currently, ursodeoxycholic acid is the most evidence-based medications for PBC. However, approximately 40% of patients with PBC respond incompletely to treatment with ursodeoxycholic acid. Therefore, several new medications are being studied in the treatment of＂poorly responsive＂ PBC, including glucocorticoids, immunosuppressants, fibrates, antiretroviral, rituximab, and some possible combination therapies. |
| |
| Keywords: | primary biliary cirrhosis medications ursodeoxycholic acid |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
